Balancing GDMT and Hyperkalemia – Expert Insights into Optimal Heart Failure Care
Released On
October 25, 2025
Expires On
October 28, 2026
Media Type
Internet
Completion Time
60 minutes
Specialty
Cardiology
Topics
Heart Failure, Hyperkalemia
Providers/Grant Support
This activity is jointly provided by Partners for Advancing Clinical Education and Nexus Healthcare Education.
This activity is supported by an independent education grant from AstraZeneca.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is designed to meet the educational needs of cardiologists and heart failure specialists.
Program Overview
Access the recording of this expert-led symposium originally presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025. This interactive session explores strategies to optimize guideline-directed medical therapy (GDMT) for heart failure while effectively managing hyperkalemia. Through engaging discussions and a real-world case study, the session will highlight the importance of maintaining renin–angiotensin–aldosterone system (RAAS) inhibitor therapy, review clinical protocols for potassium monitoring, and examine the role of potassium binders in enabling continued treatment.
Goals
The aim of this activity is for learners to be better equipped to optimise heart failure management by maintaining GDMT while effectively managing hyperkalemia through evidence-based strategies, including potassium monitoring and the appropriate use of potassium binders.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Review the importance of maintaining optimal RAAS inhibitor therapy in patients with heart failure experiencing hyperkalemia
- Adhere to clinical protocols and guideline recommendations for monitoring potassium levels in patients receiving RAAS inhibitors
- Describe the role of potassium binders in hyperkalemia management, including their mechanisms of action, dosing, and key efficacy data from clinical trials and real-world studies
- Discuss the importance of adhering to RAAS inhibitors while managing potassium levels during patient education
Curriculum
Video 1: Welcome and introduction
Video 2: Maintaining balance: considering potassium levels in heart failure management
Video 3: Hyperkalemia as a barrier to heart failure treatment optimization
Video 4: Strategies to facilitate RAAS inhibitor maintenance despite hyperkalemia
Video 5: Case study: Navigating RAAS inhibition and hyperkalemia management
Gauge
GAUGE is Nexus Healthcare Education’s advanced outcome measurement tool, uniquely designed to evaluate the real-world impact of learning on clinical practice and patient care. By completing each of GAUGE's outcome assessments, you actively contribute to advancing the quality of healthcare education.
How GAUGE works
Participation tracking: GAUGE monitors your engagement, including time spent on modules and completion rates, providing insights into your commitment to learning.
Satisfaction feedback: After completing each module, you will be asked to fill out a satisfaction survey. This helps us capture your perceptions, identify strengths and pinpoint areas for improvement to continually optimise our programmes.
Knowledge assessment: Pre- and post-module quizzes are used to measure knowledge gains. These assessments are designed to ensure the programme effectively addresses your practice needs and supports your growth in clinical competence.
Competency evaluation: Using practical, case-based scenarios via the Clinical Challenge Quiz, GAUGE evaluates your readiness to apply new knowledge in real-world settings. Follow-up assessments at 1, 3 and 6 months post completion help track your confidence and ability to implement changes over time.
Performance and patient care impact: Through self-reported Patient Care Logs, GAUGE tracks the direct influence of learning on clinical behaviour and patient outcomes. Logging applications of new skills provides valuable data on patient care improvements. You are encouraged to update your log frequently, with reminders sent at 5 and 11 months after module completion of the entire series.
Faculty
Javed Butler
Distinguished Professor of Medicine
University of Mississippi Medical Center, Mississippi, USA
Ileana L. Piña
Professor of Medicine and Epidemiology
Montefiore Einstein Center for Heart and Vascular Care
Akshay S Desai
Medical Director of the Cardiomyopathy and Heart Failure Program
Brigham and Women’s Hospital, Massachusetts, USA
Roberto Pecoits Filho
Scientific Director, Ann Arbor Research Collaborative for Health, USA
Professor of Medicine, Pontifical Catholic University of Paraná, Brazil
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and Nexus Healthcare Education. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education, the Accreditation Council for Pharmacy Education, and the American Nurses Credentialing Center to provide continuing education for the healthcare team.
Physician Credit Designation
Partners designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For additional information about the accreditation of this activity, please visit https://partnersed.com.
Disclosure of Conflicts of Interest
Faculty disclosures
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
Akshay S. Desai
Received consultancy fee for providing speaker service to 89Bio, Abbott Laboratories, Alnylam Pharmaceuticals, AstraZeneca, Avidity Biosciences, Axon Therapies, Bayer Pharmaceuticals, Biofourmis, Boston Scientific Corporation, Endotronix, GlaxoSmithKline (GSK plc), Medpace Holdings, Medtronic, Merck & Co., NewAmsterdam Pharma Company N.V., Novartis, Parexel International Corporation, Regeneron, River2Renal, F. Hoffmann-La Roche, and scPharmaceuticals. Received research grants (to Brigham and Women’s Hospital) from Abbott Laboratories, Alnylam Pharmaceuticals, AstraZeneca, Bayer Pharmaceuticals, DevPro Biopharma, Novartis, and Pfizer.
Roberto Pecoits-Filho
Received consultancy fee for providing speaker services to AstraZeneca, Boehringer Ingelheim, and Novo Nordisk.
Ileana L. Piña
Served as a director, officer, partner, employee, advisor, consultant, or trustee for FDA Center for Devices and Radiological Health.
Javed Butler
Received consultancy fee from Abbott Laboratories, Adaptyx Biosciences, American Regent, Amgen (Applied Molecular Genetics), AskBio, AstraZeneca, Bayer Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb (BMS), Cardiac Dimension, Cardior Pharmaceuticals, CSL Vifor, CVRx, Cytokinetics, Daxor, Diastol, Edwards Lifesciences, Element Sciences, Eli Lilly and Company, Faraday Pharmaceuticals, F. Hoffmann-La Roche, Idorsia Pharmaceuticals, Imbria Pharmaceuticals, Impulse Dynamics, Innolife, Intellia Therapeutics, Inventiva, Levator, Lexicon Pharmaceuticals, Mankind Pharma, Medtronic, Merck & Co., NewAmsterdam Pharma Company N.V., Novartis, Novo Nordisk, Pfizer, Pharmacosmos, PharmaIN, Prolaio, Pulnovo Medical, Regeneron Pharmaceuticals, Renibus Therapeutics, Reprieve, RyCarma Therapeutics, Saillant Therapeutics, Salamandra, Salubris, scPharmaceuticals, Secretome Therapeutics, Sequana Medical, SQ Innovation, TekkunLev, Tenex, Transmural Biotech, Tricog, Ultromics, Vera Therapeutics, and Zoll.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be emailed to the participant.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and further their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information
For CME questions please contact: [email protected]